126 related articles for article (PubMed ID: 1610270)
1. [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].
de Montalembert M; Jan D; Clairicia M; Hannedouche T; Sidi D; Girot R
Arch Fr Pediatr; 1992 Mar; 49(3):159-63. PubMed ID: 1610270
[TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of post-transfusion iron overload by deferoxamine].
de Montalembert M; Llados A; Hannedouche T; Girot R
Arch Fr Pediatr; 1989 Feb; 46(2):99-105. PubMed ID: 2735804
[TBL] [Abstract][Full Text] [Related]
4. Management of iron overload with a disposable multi-day delivery system.
Paolo C; Francesco S; Sergio A
Am J Hematol; 1996 Jan; 51(1):95. PubMed ID: 8571948
[No Abstract] [Full Text] [Related]
5. Advances in the use of iron-chelating agents for the treatment of iron overload.
Modell B
Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
[No Abstract] [Full Text] [Related]
6. Iron chelating therapy in thalassemia: current problems.
Russo G
Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
[No Abstract] [Full Text] [Related]
7. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Giardina PJ; Grady RW
Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
[TBL] [Abstract][Full Text] [Related]
8. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
[TBL] [Abstract][Full Text] [Related]
9. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation.
Chandy M
J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
[No Abstract] [Full Text] [Related]
11. Reassessment of the use of desferrioxamine B in iron overload.
Propper RD; Shurin SB; Nathan DG
N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
[TBL] [Abstract][Full Text] [Related]
12. Desferal therapy in iron storage disease.
Thompson RB; Owen DM; Bell WN
Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
[No Abstract] [Full Text] [Related]
13. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
[No Abstract] [Full Text] [Related]
14. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
[No Abstract] [Full Text] [Related]
15. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
16. [First results of a new iron chelating agent in the treatment of post-transfusional hemochromatosis].
Giraud P; Orsini A; Giraud F; Pinsard N
Arch Fr Pediatr; 1965 Apr; 22(4):463-8. PubMed ID: 5826583
[No Abstract] [Full Text] [Related]
17. [Therapeutic results in the treatment of primary and secondary hemochromatoses with Desferal].
Wöhler F
Blut; 1967 Apr; 15(1):33-42. PubMed ID: 6025965
[No Abstract] [Full Text] [Related]
18. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
[TBL] [Abstract][Full Text] [Related]
19. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Wu KH; Chang JS; Tsai CH; Peng CT
Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
